LUNG CANCER: Studies of patient biopsies and preclinical models imply that activating EGFR mutations drive an immunosuppressive tumour microenvironment, and suggest synergy for combination EGFR/PD-1 inhibition.


Feb. 17, 2020


Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non–small cell lung cancer.

Science Immunology, Jan 31th 2020